



Pipeline (2026~2035)

Contact: GBCD@yungshingroup.com

No	Category	Ingredient	Strength	Dosage Form	Indication	Status
1	Adrenergic receptor agonist	Dexmedetomidine	4mcg/mL 200 mcg/2mL	Injection	Schizophrenia; Bipolar I or II disorder	Formulation in development
2	Analgesics	Acetaminophen; Caffeine	500mg; 65mg	Tablet, Film Coated	Analgesic, Antipyretic	Formulation in development
3	Antibacterials	Ceftaroline fosamil	600mg	Powder for Injection	Skin infections and community-acquired pneumonia	Formulation in development
4	Antibacterials	Ceftazidime; Avibactam	2g; 0.5g	Powder for Injection	Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia	Formulation in development
5	Antibacterials	Daptomycin	500mg	Injection (Lyophilized)	Infective endocarditis	Formulation ready
6	Antibacterials	Tigecycline	50mg	Injection (Lyophilized)	Complicated skin and skin structure infections, Complicated intra-abdominal infections, Community-Acquired Bacterial Pneumonia	Formulation in development
7	Antidepressants	Doxepin	3mg 6mg	Tablet	Atopic dermatitis, Insomnia	Formulation ready
8	Antidiabetic Agents	Alogliptin	25mg	Tablet, Film Coated	Type 2 diabetes mellitus	under review by TFDA
9	Antidiabetic Agents	Dapagliflozin	5mg 10mg	Tablet, Film Coated	Type 2 diabetes mellitus	Formulation in development
10	Antidiabetic Agents	Empagliflozin	25mg	Tablet, Film Coated	Type 2 diabetes mellitus	Formulation in development
11	Antidiabetic Agents	Empagliflozin; Linagliptin	25mg; 5mg	Tablet, Film Coated	Type 2 diabetes mellitus	Formulation in development



Pipeline (2026~2035)

Contact: GBCD@yungshingroup.com

No	Category	Ingredient	Strength	Dosage Form	Indication	Status
12	Antidotes	Sugammadex	100mg	Injection	Reversal of neuromuscular blockade	Formulation ready
13	Antifungals	Isavuconazonium sulfate	372mg	Injection (Lyophilized)	Invasive aspergillosis, Invasive mucormycosis	Formulation in development
14	Antineoplastics	Cabazitaxel	60mg/1.5mL	Injection	Prostate cancer	Formulation in development
15	Antiparasitics	Ivermectin	10mg/g	Cream	Head lice infestation, strongyloidiasis of the intestinal tract, onchocerciasis	Formulation in development
16	Antipsychotics	Lurasidone HCl	40mg	Tablet, Film Coated	Schizophrenia, Bipolar I disorder	Formulation in development
17	Antivirals	Peramivir	300mg/60ml	Injection	Influenza	Under review by TFDA
18	Antivirals	Tenofovir Alafenamide Fumarate	eq 25mg base	Tablet, Film Coated	Chronic Hepatitis B (HBV), HIV-1 infection	Formulation in development
19	Cardiovascular Agents	Sacubitril; Valsartan	49mg; 51mg 97mg; 103mg	Tablet, Film Coated	Chronic heart failure	Formulation in development
20	Cardiovascular Agents	Amlodipine; Atorvastatin	5mg; 20mg	Tablet, Film Coated	Hypertension, Coronary artery disease, Chronic stable angina, Hyperlipidemia	Formulation in development
21	Cardiovascular Agents	Nebivolol	5mg	Tablet	Hypertension	Under review by TFDA
22	Cardiovascular Agents	Olmesartan medoxomil; Amlodipine	20mg; 5mg 40mg; 5mg	Tablet, Film Coated	Hypertension	Formulation ready
23	Cytolytic Agent	Deoxycholic Acid	20mg/2mL (10mg/mL)	Injection	Reduces moderate to severe submental fat	Formulation in development



Pipeline (2026~2035)

Contact: GBCD@yungshingroup.com

No	Category	Ingredient	Strength	Dosage Form	Indication	Status
24	Estrogen receptor antagonist/modulator; Osteoporosis agent	Raloxifene	60mg	Tablet, Film Coated	Treats/prevents postmenopausal osteoporosis and reduces invasive breast cancer risk	Formulation in development
25	Hypolipidemic agent	Rosuvastatin; Ezetimibe	10mg; 10mg	Tablet, Film Coated	Osteoporosis	Formulation in development
26	Muscle relaxant	Rocuronium bromide	10mg	Injection	Skeletal muscle paralysis for intubation and surgery/ventilation	Formulation ready
27	Proton pump inhibitor (PPI)	Vonoprazan	20mg	Tablet, Film Coated	Erosive esophagitis; Helicobacter pylori infection	Formulation in development
28	Sleep Promoting Agents	Lemborexant	5mg	Tablet	Insomnia	Formulation in development